Respiratory infectious diseases
Conditions
Interventions
Intervention group:cangma pill
control group:Carbocysteine
Sponsors
Beijing Hospital of Traditional Chinese Medicine, Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: The diagnostic standard of dampness syndrome of spleen deficiency is made by referring to the Chinese Medicine Industry standard of the People's Republic of China-Chinese Medicine Syndrome Diagnosis Standard: wheezing cough and chest tightness, sputum is easy to cough, sputum is sticky or spit is not comfortable, the chest is stuffy, the mouth is greasy, stomach cavity and abdominal distension. The tongue is pale, the tongue coating is white and greasy, the pulse string is slippery. Inclusion criteria 1) Patients with stable bronchiectasis diagnosed which conforms to the western medicine and airway mucus hyper-secretion assessment; 2) Patients with bronchiectasis presented as syndrome of spleen deficiency and dampness in Chinese medicine; 3) Aged between 18 and 80 years old; 4) Able to understand and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1)Patients with dry bronchiectasis (clinical symptoms only include hemoptysis); 2)Patients with acute exacerbation of bronchiectasis (the definition of acute exacerbation is based on the clinical judgment of the expert consensus on the diagnosis and treatment of adult bronchiectasis in 2020 edition); 3)Complicated with serious cardiovascular and cerebrovascular complications and serious gastrointestinal diseases; 4)The value of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are 1.5 times higher than the upper limit of normal value, and creatinine (Cr) is more than the upper limit of normal value; 5)Patients with various organ tumors; 6)Pregnant and lactating women; 7)Known allergy to the test drug; 8)Participated in other clinical trials within three months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CASA_Q;Sputum volume; | — |
Secondary
| Measure | Time frame |
|---|---|
| The number of acute exacerbations within 3 months of follow-up;Physical and chemical properties of sputum: ratio of dry/wet weight of sputum.;Decline rate of FEV1 in lung function;VAS scores; | — |
Countries
china
Contacts
Public Contactmeng liu
Outcome results
None listed